Immunotherapy against cancer: How therapeutic antibodies do their job

A look at cancer cells: Thanks to an innovative method of super-resolution microscopy, researchers observed with molecular resolution in 3D how therapeutic antibodies attack and alter B cells, thereby inducing their destruction. Their research presents the new type of molecular 3D visualization of antibody-cell interactions. The visualization of the molecular interaction between antibody and tumor… Continue reading Immunotherapy against cancer: How therapeutic antibodies do their job

Immunotherapy against cancer: How therapeutic antibodies do their job

A look at cancer cells: Thanks to an innovative method of super-resolution microscopy, researchers observed with molecular resolution in 3D how therapeutic antibodies attack and alter B cells, thereby inducing their destruction. Their research presents the new type of molecular 3D visualization of antibody-cell interactions. The visualization of the molecular interaction between antibody and tumor… Continue reading Immunotherapy against cancer: How therapeutic antibodies do their job

T cells’ capability to fully prevent acute viral infections opens new avenues for vaccine development

Scientists have discovered that T cells — white blood cells that can destroy harmful pathogens — can completely prevent viral infection, to an extent previously thought only possible due to neutralizing antibodies. Their findings reshape our understanding of how our immune system works, paving the way for the design of more effective vaccines.

Experts Forecast Cancer Research and Treatment Advances in 2025

Every new year brings excitement and anticipation for what might happen over the next 12 months. So, what’s in store for 2025 that could change the way we diagnose and treat cancer? What first-in-class therapeutics could offer new life-saving options to patients? What scientific discovery will have everyone talking?  In 2024, we saw the approval… Continue reading Experts Forecast Cancer Research and Treatment Advances in 2025

New therapeutic target could boost CAR T-cell therapy success in solid tumors

Russell W. Jenkins, MD, PhD, a physician investigator in the Krantz Family Center for Cancer Research at the Mass General Cancer Center and an assistant professor of Medicine at Harvard Medical School, is senior author of a new study in Cancer Immunology Research, “TBK1 is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy… Continue reading New therapeutic target could boost CAR T-cell therapy success in solid tumors